Drugs / PC-mAb
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03320265 | Oct 2017 → Mar 2018 | arteritis | Athera Biotechnologies AB | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PC-mAb | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03320265 ↗ |
| Modality | Monoclonal antibody | “Phosphorylcholine human monoclonal antibody” NCT03320265 ↗ |
| Route | Intravenous | “Phosphorylcholine human monoclonal antibody, i.v. infusions” NCT03320265 ↗ |